Generation of α1G Transgenic Lines
The α1G transgenic mouse lines were generated using BAC clone RP23-65I14 (NCBI accession number AL645965) obtained from the BACPAC Resource Center at Children's Hospital Oakland Research Institute (Oakland, CA) that contains the complete genomic sequence of the
Cacna1g gene. Along with the gene of interest, the BAC included the
Abcc3 and
Ankrd40 genes, neither of which are suspected to produce a neurological phenotype. The
Abcc3 gene encodes an ATP-binding cassette transporter belonging to the multidrug resistance protein family, and primarily functions as an efflux pump transporting glucuronides, glutathione conjugates, and bile acids (
Kruh et al., 2001;
Belinsky et al., 2005). The
Ankrd40 gene expresses a novel, uncharacterized non-channel protein containing ankyrin repeat domains, commonly associated with protein-protein interactions (
Li et al., 2006). Since the
Cacna1g promoter region and other relevant regulatory elements have not yet been defined, the BAC transgene was not further engineered in order to preserve the endogenous expression pattern.
Bacterial cells possessing the BAC were cultured overnight, and BAC DNA was purified by anion-exchange chromatography using NucleoBond AX 500 columns (BD Biosciences Clontech, Palo Alto, CA) according to the manufacturer's protocol. The isolated BAC transgene was microinjected into the pronuclei of fertilized eggs from FVB mice at The Darwin Transgenic Mouse Core Facility at Baylor College of Medicine. Two transgene positive founder lines and all subsequent transgenic progeny were identified by PCR amplification of mouse tail DNA using the genotyping primers 5′-CACCCGACATAGATAATAACTTCG-3′ and 5′-ACGTAGATGGAGTGGACACATTG-3′ (Integrated DNA Technologies (IDT), Coralville, IA). Mice were housed on a 12-hour light-dark cycle and allowed to feed and drink ad libitum. Mouse handling and experimental procedures were conducted in accordance with the guidelines of the US National Institutes of Health, as approved by the Animal Care and Use Committee of Baylor College of Medicine.
Determination of Transgene Copy Number
Genomic DNA isolated from transgenic mice and their respective wildtype (WT) littermates was analyzed by real-time quantitative PCR to determine the number of transgene integrations using the comparative CT method (ΔΔCT method). Amplification of the target gene, Cacna1g, was performed using the exonic forward primer 5′-TGGAACTGCCCATCATGAGAT-3′ and the intronic reverse primer 5′-CCTCATTCTGCTGTCCTGCTAAT-3′, while amplification of the control gene, Scn5a, was achieved using the intronic forward primer 5′-AGGGTTTCTCTGTGACCCAAAC-3′ and the exonic reverse primer 5′-AGAGCTACGGGACACAGTATCCA-3′ (IDT). The resulting amplicons were detected using dual-labeled TaqMan probes synthesized by Applied Biosystems (Foster City, CA) spanning an exon-intron boundary of the Cacna1g gene (5′-6FAM-ATCACCGGTAAGGGAATGCATGCCAC-TAMRA-3′) and an intron-exon boundary of the Scn5a gene (5′-6FAM-CTTCCCCTACCCTTTTCCAGGCTCTCA-TAMRA-3′) to ensure the detection of amplified genomic DNA. To determine transgene copy number, the fold change in amplification of the Cacna1g gene versus the control Scn5a gene was calculated using the ΔΔCT method, where fold change equals 2−ΔΔCT and ΔΔCT = ΔCT, transgenic − ΔCT, WT = (CT, av, Cacna1g − CT, av, Scn5a) − (CT, av, Cacna1g − CT, av, Scn5a). The estimated fold change was then doubled and subtracted by two to determine copy number; since the Cacna1g amplification results were normalized to the reference Scn5a gene that is present at two copies, and two copies of the Cacna1g gene are endogenously found within the mouse genome. The average threshold cycle (CT), which indicates the fractional cycle number of amplified PCR product that reaches a fixed threshold value, was determined for each sample by running five technical replicates.
Rotarod Test for Motor Coordination
Adult (~ 2-month-old) naïve transgenic and WT mice were placed atop a 3 cm diameter rotating rod accelerating linearly from 4 to 40 rpm over 5 minutes (Ugo Basile, Comerio, Italy). Motor coordination was tested for three consecutive days with four trials per day while allowing the mice a recovery period of at least 30 minutes between trials. Each trial concluded after the mouse fell from the rod, held on to the rod for four consecutive 360-degree rotations, or achieved the maximum trial length of 300 seconds. Times for each trial were evaluated for each transgenic mouse line compared to WT mice.
Quantitative RT-PCR Analysis
To measure the mRNA produced from the transgene, RNA isolated from transgenic mice and their respective WT littermates was analyzed by real-time quantitative RT-PCR (qRT-PCR). RNA was extracted from adult brain and heart samples using TRIzol Reagent (Invitrogen, Carlsbad, CA) and then purified from contaminants using the RNA Cleanup protocol provided in the RNeasy Mini Kit (Qiagen, Valencia, CA) to produce pure, high-quality RNA. Thalamic RNA was extracted from dissected samples following the purification protocol outlined in the RNeasy Mini Kit (Qiagen). Total RNA was appropriately diluted and then reverse transcribed with random hexamer primers using the SuperScript III First-Strand Synthesis System (Invitrogen), according to the manufacturer's protocol. Pre-designed Taqman assays detecting the expression of the target gene, Cacna1g (Applied Biosystems; assay ID: Mm00486549_m1), and the endogenous controls, eukaryotic 18S rRNA (Applied Biosystems; product number 4319413E) and mouse GAPD (Applied Biosystems; product number 4352932E), were compared between transgenic and WT samples to determine the fold change in expression using the ΔΔCT method, as described above.
Western Blotting
Membrane proteins were isolated from adult whole brain samples from transgenic mice and their respective WT littermates by homogenization in a cold buffer solution consisting of 50 mM Tris-HCl (pH 7.4), 1 mM EGTA (pH 8.0), 1 mM DTT (Sigma-Aldrich, St. Louis, MO), 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich), 2 μg/ml pepstatin (Roche, Indianapolis, IN), 4 μg/ml calpain I (Sigma-Aldrich), 4 μg/ml calpain II (Sigma-Aldrich), and Complete Protease Inhibitor Cocktail (Roche). Homogenized samples were centrifuged at 1,000 g for 5 minutes and the resulting supernatant centrifuged at ~100,000 g for 1 hour, with the protein pellet resuspended in the above homogenization buffer supplemented with 0.1% Triton X-100 (Fisher Scientific, Pittsburgh, PA). Samples containing 50 μg of protein, as quantified by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA), were mixed with sample buffer containing 2% SDS and heated at 70°C for 10 minutes. The protein samples were then electrophoretically separated on 10% polyacrylamide gels (Bio-Rad) and transferred to PVDF membranes (Santa Cruz Biotechnology, Santa Cruz, CA) using Bjerrum and Schafer-Nielsen buffer with 0.037% SDS at 100 volts for 105 minutes at 4°C. Membranes were blocked with 5% non-fat dry milk (Bio-Rad) in TBS with 0.05% Tween 20 (Bio-Rad) to prevent non-specific antibody binding. The Cacna1g protein was detected using the anti-Cav3.1 primary antibody (Alomone Labs, Jerusalem, Israel) at a 1:200 dilution, and visualized using Amersham ECL reagent (GE Healthcare, Piscataway, NJ) after binding of the horseradish peroxidase-labeled secondary antibody (Santa Cruz Biotechnology) and exposure to HyBlot CL film (Denville Scientific, Metuchen, NJ).
In situ Hybridization
RT-PCR was performed using the SuperScript III First-Strand Synthesis System (Invitrogen) with 50 ng of wild-type adult mouse brain RNA and random hexamer primers following the manufacturer's protocol. The resulting cDNA was subsequently amplified using primers spanning exons 37 and 38 of the Cacna1g gene that introduced SP6 and T7 promoter sequences to produce a DNA template for riboprobe production. The PCR amplification reaction used the forward primer 5′-GCGATTTAGGTGACACTATAGATCCTACAGCTTCCCAAAGATGC-3′ and the reverse primer 5′-GCGTAATACGACTCACTATAGGGGAAGACAAACCAGAGAGACTCAGC-3′ with the SP6 and T7 promoter sequences designated in bold type and the sequence specific to the Cacna1g gene underlined (IDT). In vitro transcription of the DNA template using the SP6 and T7 promoters in the presence of digoxygenin-tagged UTP generated the sense and antisense RNA probes.
Tissue preparation, automated ISH, and digital imaging were performed as previously described (
Yaylaoglu et al., 2005) and as described online at
http://www.genepaint.org/RNA.htm. Briefly, brains from both lines of adult transgenic mice, along with WT littermate controls, were removed and immediately frozen by placing samples atop a dry ice/ethanol bath. Frozen samples were sectioned (25 μm thickness) using a cryostat with a distance between sections of 200 μm and mounted on glass slides. Antisense
Cacna1g probe was hybridized to sections and detected by catalysed reporter deposition (CARD) using biotinylated tyramide followed by colorimetric detection of biotin with avidin coupled to alkaline phosphatase. This results in a dark blue precipitate in cells containing the
Cacna1g transcript, while hybridization with the sense control probe produces no signal. The amount of precipitate is proportional to the number of detected transcripts, and gene expression strength is detectable via the Celldetekt program (
Carson et al., 2005), with red cells showing strong expression, blue cells displaying intermediate expression, and yellow cells representing weak expression.
Thalamic Patch-Clamp Recording
Coronal brain slices (350 μm thick) prepared from P13-17 day-old transgenic and WT littermate mice from each transgenic line were collected as in previous studies (
Zhang et al., 2002,
2004) at the level of the lateral dorsal nucleus (LDN; see figures 41-43,
Paxinos and Brown, 2001) or the vental basal nucleus (VB; see figures 44-46,
Paxinos and Brown, 2001) of the thalamus. These regions were selected since their relay cells are synaptically linked to frontal brain regions where absence seizures are known to be the most prominent in mice and human. Thalamocortical relay cells within the LDN and VB were visually identified with infrared optics, and recorded by the whole-cell patch clamp method to measure T-type calcium currents and voltage dependence of steady-state inactivation (SSI). Electrophysiological recordings were conducted using voltage protocols and solutions as previously described (
Zhang et al., 2002,
2004). Data collection followed strict selection criteria to standardize recording variability based upon size, clamp quality, and cell condition (absence of significant time-dependent calcium current rundown within the recording time interval). Current amplitude from the inactivation protocol, normalized to maximum, was plotted as a function of prepulse membrane potentials, and best-fitted with a Boltzmann function:
I/Imax = {1+ exp(
V-
V1/2)/
k}−1, where
V1/2 and
k represent the half-maximal voltage and slope, respectively. Cell capacitance measurements were estimated using the built-in program within the pClamp10 software. Briefly, the “Membrane Test” in Clampex generates a definable, biphasic voltage pulse. The current response is measured and capacitance is then calculated using Ohm's law.
Simultaneous Electroencephalograph (EEG) and Electrocardiogram (ECG) Recordings
Transgenic and WT control mice ranging from 1-2 months of age were surgically implanted under avertin anesthesia with a microminiature connector attached to silver wire electrodes (0.005-inch diameter). EEG electrodes were positioned through cranial burr holes overlying the cortical surface in the subdural space over the brain, and two ECG electrodes running laterally within the subcutaneous tissue on either side of the heart were secured with sutures. After one or more days of post-surgical recovery, cortical EEG and ECG activity of freely moving mice was recorded for several hours per session over multiple days using a digital video monitoring system (Stellate Systems, Harmonie software, versions 5.0b and 6.1c, Montreal, Quebec, Canada). EEG recordings were collected from 8 α1G-Tg1 mice and 6 α1G-Tg2 mice, while ECG recordings were gathered from at least 3 mice from each transgenic line. To determine the seizure-sensitivity to anti-epileptic drug treatment, mice from each transgenic line were intraperitoneally injected with either a 5 mmol/kg dose of ethosuximide (Sigma) or a saline vehicle control. Drug effects were assessed by comparing seizure incidence during an initial one-hour baseline EEG recording period with that observed in the hour immediately following injection of either ethosuximide or saline. EEG and ECG recordings from WT, α1G-Tg1, and α1G-Tg2 mice were analyzed to determine the number of seizures per hour, average SWD frequency, average seizure duration, and average heart rates.
Video-EEG and -ECG recordings were analyzed by an individual blinded to the genotype of the animal while ensuring each animal examined displayed similar states of arousal and background activity. The behavioral phenotype of the recorded mice was assessed by reviewing the digital video associated with each SWD event to identify episodes of behavioral arrest typified by interrupted motor activity during the seizure and/or a myoclonic jerk at the end of the seizure.
Statistical Analysis
The transgene copy number, rotarod, and qRT-PCR experiments along with EEG discharge and ECG activity characterizations were analyzed using the one-way ANOVA test. Cacna1g protein levels by Western blotting were quantified by densitometry and analyzed using a one-tailed paired t-test. Electrophysiology data analysis was performed using the Student's t-test or one-way ANOVA with the post hoc test. All data are represented as the mean ± SEM.